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Phosphodiesterase inhibition has received much attention in the past 20 years for the potential treatment
of CNS disorders. A primary focus of this work is the enhancement of memory and/or cognitive
functioning. The role of PDEs in the augmentation of cyclic nucleotide signaling makes these enzymes
attractive targets for enhancing the effects of neuronal communication. This review focuses on recent
ﬁndings with respect to the role of PDE2 inhibition in cognitive functioning. Special attention is paid
to recently disclosed, selective tool compounds and the use of these tool compounds to support the role
of PDE2 inhibition in cognition. Recently reported SAR and modeling work will be presented along with
discussion of the entry of new PDE2 inhibitors into the clinic.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.Impairments in memory and cognitive function are a signiﬁcant messengers are tightly regulated by control over intracellular
world health problem. Memory and cognitive decline are a major
health complaint of people as they age, and have a signiﬁcant
impact on daily functioning.1 Even more pronounced are the cog-
nitive deﬁcits prominent in neurodegenerative and psychiatric dis-
orders such as Alzheimer’s, depression, and schizophrenia. Clearly,
there is a signiﬁcant medical need for new drugs which delay or re-
verse these cognitive deﬁcits. A large body of research has been
conducted to determine the fundamental biological mechanisms
underlying memory and cognition. To date, most drug discovery
investigations in this area focus on speciﬁc neurotransmitter sys-
tems thought to be involved in cognitive functioning. Prominent
among these systems are the acetylcholine, serotonin, histamine,
glutamate, and dopamine systems.2 While direct intervention in
these systems has certainly led to some success in the ﬁeld, an-
other approach is to target enhancement of the downstream sig-
naling cascades which trigger the long term transcriptional and
structural response to neuronal activity that underlies the forma-
tion of long term memories.3 This review will focus on the poten-
tial role for phosphodiestersase 2 (PDE2) inhibitors in the
treatment of cognitive disorders. Speciﬁcally focusing on recent
SAR and new tool compounds discovered over the last 5 years,
and the evidence these tools have generated to support the thera-
peutic potential of PDE2 inhibitors. cAMP and cGMP are ubiquitous
second messengers that modulate a wide array of intracellular pro-
cesses. The diverse biological actions controlled by these secondlocalization, as well as temporal residence. Phosphodiesterases
(PDEs) are the enzymes which metabolically inactivate these sec-
ond messengers through hydrolysis of the cyclic phosphate, and
are therefore critical for the termination of cGMP and cAMP signal-
ing cascades. To date 21 separate genes encoding individual PDE
isoforms have been identiﬁed in mammalian cells. These are clas-
siﬁed into 11 families each family containing 1–4 isoforms.4,5 The
sub-classiﬁcations of PDEs are determined by different preferences
for cAMP or cGMP as substrates, and the different regulatory do-
mains contained within each family of enzyme. For instance, PDEs
4, 7, 8 speciﬁcally hydrolyze cAMP; PDEs 5, 6, 9 speciﬁcally hydro-
lyze cGMP; and PDEs 1, 2, 3, 10, 11 are considered dual speciﬁcity
enzymes, hydrolyzing both cAMP and cGMP. The PDEs can also be
classiﬁed by the different regulatory domains which modulate
their activity, such as regulation by binding of cGMP to GAF do-
mains, or modulation of PDE1 by Ca2+/calmodulin, or the presence
of speciﬁc protein-binding regions, or phosphorylation sites.6
As a result of their importance in the cell signaling cascade,
PDEs have become important biological targets for therapeutic
intervention in a variety of disorders. The best known of these
are the PDE5 inhibitors marketed for the treatment of erectile dis-
function and pulmonary artery hypertension (sildenaﬁl, tadalaﬁl,
vardenaﬁl). In addition, PDE4 inhibitors have been approved for
the treatment of COPD (roﬂumilast), and PDE3 inhibitors for acute
treatment of congestive heart failure (milrinone). While the cur-
rently approved uses of PDE inhibitors are for peripheral indica-
tions. There has also been signiﬁcant interest in PDE inhibitors
for the treatment of CNS disorders, due to the role of PDEs in ter-
minating transcriptional cascades triggered by cAMP and cGMP
up-regulation which may impact neuronal plasticity. For example,
the second messenger cAMP, synthesized from ATP by adenylate
cylcase, activates protein kinase A (PKA) which phosphorylates
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by affect transcription of genes related to synaptic plasticity and
survival, like brain-derived neurotrophic factor (BDNF).7 Con-
versely, cGMP is derived from GTP by guanylyl cyclase (GC), which
is activated by nitric oxide (NO). The NO/cGMP pathway activates
protein kinase G (PKG), which can also induce CREB phosphoryla-
tion.8 Both the cAMP/PKA/CREB and the cGMP/PKG/CREB pathway
are implicated in long-term potentiation (LTP), which is considered
the neurophysiological correlate of memory.9,10 The importance of
cAMP and cGMP in the propagation of signaling cascades which
provoke gene expression changes as a result of neuronal activity
have made PDEs popular targets for intervention in CNS disorders.
Some recent reviews cover general PDE inhibition, and the phar-
macological evidence for their potential use in the treatment of
CNS disorders.6,11,12
The different PDE isoforms vary in their expression levels in dif-
ferent brain regions.11 As a result many of the known PDE isoforms
have been targeted for CNS disorders. Inhibitors of atleast 7 of the
PDE families have been evaluated in pre-clinical models of CNS dis-
orders, speciﬁcally PDEs 1, 2, 4, 5, 7, 9, 10, and 11. General reviews
of these efforts have been cited above. In addition to pre-clinical
evaluations, inhibitors of PDEs 1, 2, 4, 9 and 10 have recently ad-
vanced to the clinic for evaluation in psychiatric and cognitive dis-
orders. It appears that clinical programs on PDE4 and PDE10
inhibitors have been slowed by dose limiting toleration issues or
lack of a strong efﬁcacy signal.13 PDE1, PDE2, and PDE9 inhibitors
have only recently gone into clinical development so human safety
and efﬁcacy data are not yet available.
Despite the considerable attention PDEs have received within
the CNS drug discovery community, PDE2 has been a somewhat
neglected member of the class. Signiﬁcant drug discovery work
on PDE2 inhibitors for CNS disorders seems to have kicked off
about year 2002. This is surprising given the high expression of
PDE2 in limibic structures such as cortex, amygdala, and hypocam-
pus, and relatively little expression detected in midbrain, hind-
brain, and cerebellum. PDE2 also has relatively low expression in
peripheral tissues which may be of value in avoiding cardiovascu-
lar and other side effects seen with some PDE inhibitors.14 This het-
erogeneous and selective distribution in forebrain structures
suggests that PDE2 may modulate neuronal signaling of complex
integrated functions such as learning, memory, and emotion. In
addition, the apparent role of PDE2 at the interface of both the
cAMP and the cGMP signaling cascades provides unique possibili-
ties for PDE2 as an integrator of these pathways, both of which
have been shown to effect memory.15
The existence of a PDE2 isoform was originally postulated in re-
sponse to the ﬁnding that bovine heart tissue preparations had
cAMP hydrolytic activity which could be affected by changing
cGMP concentrations. This lead to PDE2’s characterization as the
mediator of cGMP dependant cAMP hydrolysis.16–18 PDE2 was later
recognized as a dual speciﬁcity enzyme, capable of hydrolyzing
both cGMP and cAMP. Excellent X-ray structural studies have been
published recently on full length PDE2 by Pﬁzer researchers. These
studies provide a strong structural rationale for how cGMP binding
to the GAF-B domain of PDE2 modulates hydrolytic function of the
enzyme.19 This ability to modulate activity in response to cGMP al-
lows the enzyme to function as a source of ‘cross-talk’ between the
cGMP and cAMP signaling cascades.
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PDE2 inhibitors in drug discovery was the limited availability of
selective inhibitors to evaluate PDE2 pharmacology. Early work
on PDE2 inhibitors involved the use of tool compounds such as
EHNA. However, this compound was subsequently found to lack
the requisite selectivity and potency for conclusive pharmacologi-
cal evaluation.20 A watershed tool compound for evaluating PDE2
inhibition was BAY-60-7550. The compound was ﬁrst described
in a 2002 patent application by Bayer.21 BAY-60-7550 inhibits
the hydrolytic activity of puriﬁed PDE2 (IC50 = 0.002 lM) and is
selective with respect to other PDE isoforms (50-fold over PDE1C,
>100-fold selectivity vs other PDE isoforms). The compound also
elevated cGMP and cAMP levels in stimulated primary neuronal
cultures in a dose responsive manner.22 In hippocampal slice prep-
arations, BAY-60-7550 enhanced LTP in response to electrical stim-
ulation supporting the potential role of PDE2 inhibitors in learning
and memory. Rodent behavioural models with BAY-60-7550 also
support the role of PDE2 in learning and memory. BAY-60-7550 en-
hanced learning in both a novel object recognition task and a social
recognition task in rats.22 In addition BAY-60-7550 improved the
acquisition and consolidation phases of novel object memory in
age impaired rats.23 More recently studies have shown that BAY-
60-7550 improves performance on object location and recognition
tasks when administered after training, suggesting the effects of
PDE2 inhibition on memory are likely due to enhanced consolida-
tion rather than attention.24,25 BAY-60-7550 shows anxyolytic ef-
fects in stressed mice using both the elevated plus maze and
hole-board tasks.26 Furthermore, Bay 60-7550 reversed corticoste-
rone-induced down-regulation of BDNF, and produced antidepres-
sant-like effects in stressed mice, supporting a potential role for
PDE2 in cognitive impairment related to stress.27 While the poor
pharmacokinetic properties of BAY-60-7550 probably preclude
its use in clinical studies, the compound has been a critical tool
for validating the potential therapeutic utility of PDE2 inhibition.
Recently, the crystal structure of a PDE2a construct bound to
BAY-60-7550 was published at a resolution of 1.9 Å, along with
the PDE2a apo structure at 2.0 Å resolution.28 The authors showed
that BAY-60-7550 binds to the active site of the enzyme and inter-
acts with the conserved glutamate residue Gln859. This speciﬁc
residue is part of the so-called ‘glutamine-switch’ responsible for
the dual cAMP/cGMP speciﬁcity of PDE2a. Interestingly, when
compared to the PDE2a apo structure, it appears that upon binding
BAY-60-7550 induces a conformational change of the enzyme
revealing a new hydrophobic pocket which can accommodate the
propylphenyl group of BAY-60-7550. The authors argued that the
origin of the high PDE2a selectivity of the compound over other
members of the PDE family could be due not only to binding to
the glutamine switch, but also to this new induced hydrophobic
pocket that is not found in any other published PDE-inhibitor com-
plexes.
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Neuro3d (now Evotec). This compound inhibits PDE2 activity with
IC50 of 0.05 lM and displays good selectivity against PDE3 and
PDE4 with 23% and 14% inhibition at 10 lM, respectively.29 The
SAR presented in this patent application suggests that the amide
functionality present on the phenyl group plays a key role for the
efﬁcient binding to PDE2. Indeed, reduction of the amide function-
ality to a cyano group (3) results in a compound with 10-fold loss
in PDE2 potency. Recently an extensive molecular modeling study
was reported by Hamza and Zhan, in which ND-7001 and
BAY-60-7550 were evaluated in molecular dynamics simula-
tions.30 The authors propose that the PDE2 catalytic site adopts
multiple conformations and that the amide of ND-7001 serves as
the primary anchor point with Gln 859, thereby orienting the
ligand in the proper orientation. Subsequently, the core of the
ligand occupies the hydrophobic pocket involving Ile826 and
Phe862 leading to additional favorable interactions (such as hydro-
phobic p–p and dipole–dipole) which contribute to the observed
PDE2 potency of this compound. Biochemically, ND-7001 increases
cGMP levels in primary neuronal cultures of rat cerebral cortical
neurons but does not increase cAMP which is in contrast with
Bay 60-7550.22 In a patent application published in 2005,29
Neuro3d reports that ND-7001 was efﬁcacious at 0.3, 3 and
30 mg/kg in the mouse forced swim test with signiﬁcantly shorter
time of relative immobility than control animals (acute stress). In
addition, ND-7001 produces anxiolytic effects in a number of tests
such as light–dark and marble burying, as well as in the elevated
plus-maze and hole-board tests.22
A phase I clinical trial was conducted with ND-7001 to investi-
gate safety, tolerability and pharmacokinetics. The compound was
reported to be safe and well tolerated to high doses and produced
no sedation, memory disturbance or withdrawal effects.31 A multi-
ple-dose study using qEEG recording to assess its effects on the
CNS and to ascertain an active dose range was planned, but no fur-
ther development has been reported since 2008.
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In 2010 Wyeth published the ﬁrst patent application disclosing
dual PDE2/10 inhibitors.32 This series of substituted imidazopyri-
dotriazine analogs showed good inhibitory activity, as exempliﬁed
by their lead compound 4 with IC50 values of 0.004 lM and
0.021 lM for PDE2 and PDE10, respectively. At the behavioral level,
this compound when dosed orally improves performance in the
object recognition test at 2.5 and 5 mg/kg, is efﬁcacious at 5 mg/
kg in an acute stress test (force swim), and produces anxiolytic ef-
fects at 5 mg/kg (light and dark test). The same year, Wyeth and
Biotie Therapies GMBH published a patent application33 on a re-
lated series of analogs. These benzimidazotriazine analogs are also
dual PDE2/10 inhibitors. Although the patent states efﬁcacy in ro-
dent models of depression, anxiety, and cognition, no speciﬁc com-
pound data is reported. No further development was reported
around this series of inhibitors.
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4Following the discovery of the tricycle series (Structure A), it
appears that the original researchers investigated a number of bio-
isosteric replacements in order to presumably improve potency,
selectivity and pharmacokinetic properties of the initial series.
After Biocrea was spun-out of Biotie Therapies GMBH in September
2010, a peer-reviewed article from Biocrea in collaboration with
Pﬁzer was published.34 This Letter describes phenylpyrazine ana-
logs as PDE10A inhibitors with some degree of selectivity against
PDE2 (Structure B). In 2012, now under the name Boehringer Ingel-
heim International Gmbh, the same authors further modiﬁed the
tricyclic series and published a patent application disclosing triazo-
loquinoxaline as PDE2 and/or PDE10 inhibitors (Structure C).35 A
number of analogs demonstrated moderate selectivity of about
15-fold for PDE2a over PDE10, as exempliﬁed by compound 5
(PDE2 IC50 = 0.004 lM; PDE10 IC50 = 0.045 lM). Interestingly,
incorporation of an aliphatic side chain on the phenyl ring resulted
in much improved selectivity against PDE10 (greater than 250-
fold). Such modiﬁcation does not seem to affect PDE2 activity but
rather disrupts binding to PDE10, as exempliﬁed by compound 6
(PDE2 IC50 = 0.003 lM; PDE10 IC50 >1 lM). Similar SAR trends
were observed in the earlier application from Wyeth/Biotie. These
patents report pro-cognitive, antidepressant, anxiolytic, and anti-
convulsant effects in in vivo models in rodents. The same year Bio-
crea announced the completion of an asset purchase and licensing
deal with Boehringer Ingelheim which includes, among other pro-
grams, the exclusive global rights of BioCrea’s PDE2 inhibitors and
its most advanced compound BCA909 (structure unknown).36
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Since the initial disclosure of the triazolopyrazine core by
Boehringer Ingelheim International Gmbh in 2012, two additional
institutions have recently reported PDE2 inhibitors containing a
similar chemotype. Work from Janssen on the initial exploration
of phenyl substitutions provided insight into the potential active
conformation of the polyaromatic system. Introduction of an o-
chloro-phenyl derivative seems to increase potency at both the
PDE2 and PDE10 enzymes suggesting that distorting coplanarity
between the two aromatic systems is favorable for binding. This
structural modiﬁcation resulted in seven to ninefold increase in
activity at both enzymes as exempliﬁed by compounds 7 (hPDE2
IC50 = 0.030 lM; rPDE10 IC50 = 0.045 lM) and 8 (hPDE2
IC50 = 0.004 lM; rPDE10 IC50 = 0.035 lM; hPDE10 IC50 = 0.033 -
lM).37 It should be noted that similar SAR trends were observed
in the earlier patent application covering triazolopyrazine ana-
logs.35 Interestingly, basic centers were found to be tolerated
which provided analogs with an acceptable overall physiochemical
proﬁle. Compound 9 showed a brain/plasma ratio of 0.62 when
dosed subcutaneously in rats. A micro-dosing experiment in rats
demonstrated that this compound reached high levels in the brain
and was primarily distributed in the striatum where both PDE2
and PDE10 enzymes are highly expressed (dose = 0.03 mg/kg iv;
drug concentration = 70 ng/g after 5 min). Compound 9 is a potent
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0.033 lM) and more than 600-fold selective against other PDEs
tested. Compounds from this invention are reported to increase
cAMP and cGMP levels in the hippocampus and striatum in rats.38
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Lundbeck also published a number of patent applications re-
lated to triazolopyrazine analogs. They described PDE2a and/or
PDE10 inhibitors containing additional modiﬁcations to the left-
hand side of the core.39 Coincidentally, the compounds described
in these applications also have the o-substituted phenyl ring de-
scribed in the Janssen work. Compounds 10 and 11 display similar
PDE2/10 selectivity proﬁle with PDE2 IC50 = 0.021 lM; PDE10
IC50 = 0.506 lM (24-fold selectivity) and PDE2 IC50 = 0.069 lM;
PDE10 IC50 = 1.76 lM (25-fold selectivity) respectively. Interest-
ingly, the incorporation of the methylether functionality seems to
increase activity at both enzymes, as exempliﬁed by compound
12 with PDE2 IC50 = 0.006 lM; PDE10 IC50 = 0.009 lM.
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Pﬁzer recently published a novel series of pyrazolopyrimidine
PDE2 inhibitors. In this series, compound 13 was found to be a po-
tent and selective PDE2 inhibitor (PDE2 IC50 = 2 nM) with >500-
fold selectivity over all other PDEs and demonstrated good brain
permeability.40
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In order to improve the PDE2a potency and ADME properties of
the series, the same group developed an alternative series. Anec-
dotally, Haning et al. published an article in 2005 describing the
importance of the central heterocylic system for efﬁcient binding
to PDE’s. In this paper, the authors compare the PDE5 inhibitory
activity of two related analogs, vardenaﬁl and sildenaﬁl.41 The
researchers argued that, despite the structural similarity of these
two analogs, the imidazolotriazine system displayed at least 10-
fold increase in potency compared to the pyrazolopyrimidine ana-
log. The authors explained that the measured potency difference
cannot be explained on the basis of X-ray crystallographic data
(due to the similar binding pattern) but rather concluded it was
due to p-stacking interactions with the two heterocyclic systems.
Coincidently, a similar structural change was incorporated onto
the initial pyrazolopyrimidine which led to a ninefold increase in
potency, as exempliﬁed by compound 14 (PDE2a IC50 = 0.009 lM)and compound 15 (PDE2a IC50 = 0.001 lM).42 It was proposed that
the nitrogen from the imidazolotriazine (labeled N1, compound
15) interacts more efﬁciently with the water molecules present
in the catalytic domain. Using free energy calculations the
researchers determined that the hydrogen bond intereactions were
energetically stronger by 1.4 kcal/mol for the imidazolotriazine
(15) compared to the pyrazolopyrimidine (14).43 After further pro-
ﬁling of compound 15, Pﬁzer advanced this analog as their clinical
compound (PF-999). This analog displayed good PDE selectivity
(2000-fold selective over PDE10) and reasonable free brain/plasma
ratio in rat (0.5). This compound increased cGMP levels in the
cerebrospinal ﬂuid of rats. Pharmacological evaluation of PF-999
in rat showed efﬁcacy in models of working memory (attenuate
ketamine-induced disruption) and spatial learning and memory
(reverse effects of scopolamine in water maze). In 2011, a phase I
clinical trial aimed at determining the safety, tolerability, and
pharmacokinetics after 14 days of treatment in healthy subjects
was completed. The compound was reported to be well tolerated
at doses between 0.1 and 60 mg. The following year a second phase
I clinical trial was completed which assessed the relative
bioavailability of a modiﬁed-release formulation at 30 mg and
120 mg.43 Pﬁzer was developing PF-999 for the treatment of
schizophrenia and no further development has been reported since
mid 2012.
Pﬁzer recently published articles discussing the discovery of a
series of potent PDE2 inhibitors identiﬁed from a PDE4 diazepi-
none scaffold.44 In silico modeling studies suggested that this ser-
ies of inhibitors would adopt a cGMP-like binding mode due to the
orientation of the ligand with Gln 859. It was thought that this
orthogonal binding mode, compared to cAMP-like binding mode
found for PDE4, would allow for greater PDE2/PDE4 selectivity.
After extensive SAR studies, the researchers identiﬁed compound
16 as their early lead. A crystal structure of the inhibitor bound
to PDE2 was obtained which conﬁrmed the initial cGMP-like bind-
ing mode. Analog 16 showed good PDE2 potency (IC50 = 0.045 lM)
and modest PDE4B selectivity (PDE4B IC50 = 0.378 lM). This com-
pound however possessed poor human microsomal stability. Fur-
ther improvement of this series focused primarily on replacing
the metabolically-labile imidazole biaryl moiety. These efforts led
to the identiﬁcation of compound 17with improved human micro-
somal stability. Additionally the rat pharmacokinetic data showed
that compound 17 (IV t1/2 = 1.5 h; Cl = 27 mL/min/kg) had an im-
proved PK proﬁle versus an early lead compound 18 (IV t1/
2 = 0.5 h; Cl = 70 mL/min/kg). Compound 17 demonstrated good
PDE2a potency (IC50 = 0.003 lM) and improved PDE4B selectivity
(PDE4B IC50 = 0.562 lM). Based on the cLogP and TPSA values,
the researchers did not expect this PDE2 tool compound to show
good brain penetration. This desirable proﬁle was then used to
study peripheral inhibition of PDE2 in rat in vivo models of osteo-
arthritis pain. When dosed subcutaneously at 10 mg/kg, compound
16 showed signiﬁcant inhibition of change in hind paw weight dis-
tribution at 1 and 3 h post-dose in the rat medial meniscal transac-
tion (MMT) model.
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In 2013 the structures of two novel PDE2 PET ligands were re-
ported in the literature. It appears that after the discovery of their
lead compound 9 as a dual PDE2/10 inhibitor with acceptable brain
uptake, Janssen decided to use this template as a starting point for
6526 L. Gomez, J. G. Breitenbucher / Bioorg. Med. Chem. Lett. 23 (2013) 6522–6527the design of their PET ligand.38 Further substitution of the phenyl
ring with a ﬂuorine atom afforded compound 19 as their desired
ligand (PDE2a IC50 = 0.001 lM; PDE10A IC50 = 0.011 lM). The
PET-ligand ([18F]-19) was used preclinically to evaluate biodistri-
bution, radiometabolite analysis and microPET imaging studies.
In the brain [18F]-19 was primarily distributed in the striatum.
The radiometabolite study showed that over 96% of the intact tra-
cer was detected in the cerebrum and cerebellum at 2 min post
injection in perfused rats versus 92% and 82%, respectively at
10 min post injection. The microPET imaging study was in accor-
dance with the biodistribution study showing that the highest con-
centration of tracer was found in the striatum at 2 min post
injection followed by hippocampus and cortex. It is worth noting
that the slowest wash-out was observed in the striatum. The
authors reported that the relative difference in tracer uptake be-
tween the startium and the reference region cerebellum stayed
constant at 2.8 up to 15 min post injection.
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Another PDE2 PET ligand was recently published by Pﬁzer.45
This imidazolotriazine compound 20 belongs to the same chemical
series recently developed by the same group, which takes advan-
tage of desirable physicochemical properties, good PDE2 potency,
low non-speciﬁc binding, and good brain permeability. The PET-li-
gand ([18F]-20) is a potent PDE2 inhibitor (IC50 = 0.0005 lM) with
good selectivity against the 10 PDE subtypes (PDE10A IC50 = 3 lM
and >20,000-fold against PDE1b/3a/4d/5a/6a/7b/8b/9a/11). The li-
gand [18F]-20 also showed >1800-fold selectivity against a CEREP
broad selectivity panel (79 targets). This analog demonstrated high
permeability, good fraction unbound in rat plasma and brain (24%
and 7.7%, respectively) as well as 17% fraction unbound in human
plasma. In vivo experiments showed acceptable free brain/plasma
ratio of 0.5 with total brain/plasma ratio of 1.56. The researchers
evaluated this PET ligand in cynomolgus monkeys and showed ra-
pid and high uptake in the striatum and low uptake in the cerebel-
lum with an in vivo binding potential of 1.51.
In addition to the chemotypes described above, additional new
structures were recently published. Merck published a patent
application describing the use of quinolones as PDE2 inhibitors
with IC50 values as low as 0.0001 lM (compound 21). No other
data were reported.46 In 2006, Altana Pharma AG published three
patent applications covering triazolophthalazine analogs as exem-
pliﬁed by compound 22 with limited data reported.47 And ﬁnally a
series of oxoindoles was reported in the patent literature48 and la-
ter discussed in a peer-reviewed article.49 The most proﬁled com-
pound, analog 23, is a potent and selective PDE2 inhibitors (PDE2
IC50 = 0.040 lM with >29-fold selectivity against the PDE sub-
types). This compound did not show any signiﬁcant inhibition
against a panel of 54 receptors and ion channels as well as 30 ki-
nases. The in vivo pharmacokinetic properties in rat appear to beN
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O
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N
S
N
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N
N
N N
MeO
21 22acceptable with low clearance (8.8 mL/min/kg) and low volume
of distribution (0.1 L/kg), leading to a moderate half-life (1.6 h)
and oral bioavailability (41%).
Since the discovery of the ﬁrst potent selective PDE2 inhibitor
BAY 60-7550 in 2002, there is now signiﬁcant pre-clinical support
for the potential role of PDE2 inhibitors in the treatment of disor-
ders with a cognitive component. As the ﬁeld stands today we now
have at least two molecules entering clinical evaluation for the
treatment of CNS disorders and imaging ligands are now available
for clinical use as well. In addition, there are now numerous selec-
tive and potent PDE2 inhibitors which can be used to further eval-
uate the pharmacology of PDE2 inhibition.
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